The latest trading day saw Recursion Pharmaceuticals (RXRX) settling at $3.18, representing a -3.34% change from its previous close.
Everyone is racing to point powerful AI models at drug discovery. A growing camp argues the real prize is the layer beneath the models — the connected biological knowledge they reason over — and that ...
In other news, X-Energy Inc. (NASDAQ:XE) earlier this month said that it sought the approval of the United Kingdom’s Generic ...
Cathie Wood’s ARK Invest ETFs sharply repositioned portfolios during the last week, highlighted by a strong buildup in SpaceX ...
A Cambridge University maths student has qualified for the 2026 Pokémon World Championships in San Francisco using skills he ...
Recursion Pharmaceuticals (RXRX) is back in focus as investors weigh fresh updates on its AI-driven drug discovery platform, along with progress in key clinical assets REC-1245 and REC-4881 and ...
Recursion Pharmaceuticals, Inc. is advancing REC-1245, an RBM39 degrader, in the DHALIA trial in solid tumors. Read more on ...
Today take a look at the basics of how to play Age of Sigmar Gloomspite Gitz- the gritty, grimy Grots from down in the grotto!
Detailed price information for Revolution Medicines Inc (RVMD-Q) from The Globe and Mail including charting and trades.
Anthropic has warned that recursive-self-improving AI could be on the horizon, but the truth is the company is more ...
Opinion
8dOpinion
When AI Builds Itself: Why Recursive Self-Learning Is the Most Important Concept in Financial Servic
Anthropic published an interesting blog post titled "When AI Builds Itself." a couple of days ago, and if you work in financial services and haven't read it, stop what you're doing. The piece ...
The researchers used machine learning on genetic sequence data to design a super-antigen containing features common across ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results